[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100488935":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":37,"locations":43,"responsibleParty":60,"collaborators":63,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":27,"eligibilityCriteria":72,"healthyVolunteers":68,"sex":73,"minAge":74,"maxAge":32,"enrollmentInfo":75,"targetDuration":32,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":88,"overallStatus":46,"whyStopped":32,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"Massachusetts General Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Palliative Care Intervention (PEACE) Group","EXPERIMENTAL","Participants will be randomly assigned, and stratified by disease, to the PEACE Group.\n\n* Participants will meet with palliative care (PC) clinician within 1 week of T-cell collection and within 72 hours of hospital admission for ACT.\n* Participants will meet with PC clinician at least 2 x weekly during hospitalization.\n* PC clinician will follow participants up to one year after randomization (or enrollment for the open pilot) and will meet participant at least 2 x weekly during inpatient hospitalizations.\n* Participants will complete follow-up study assessments on pre-determined days per protocol. The assessments will be filled out remotely or via paper.\n* Participants will complete exit interviews in the open pilot only.",[13],"Behavioral: Palliative Care",{"label":15,"type":16,"description":17,"interventionNames":18},"Usual Care Group","ACTIVE_COMPARATOR","Participants will be randomly assigned, and stratified by disease, to the Usual Care Group and will receive standard care for ACT.",[19],"Behavioral: Usual Care",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"BEHAVIORAL","Palliative Care","* Palliative care (PC) intervention tailored to ACT recipients and addressing multiple PC domains with the input of ACT clinical experts, PC clinicians, and patients and caregivers.\n* Domains discussed include therapeutic relationship, symptom management, prognostic awareness and illness understanding, coping with illness, treatment decision-making, EOL care.\n* The palliative care intervention will be refined for the randomized control trial based on the feedback from the open pilot.",[9],[27],"PEACE",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Usual Care","Standard care for ACT per the treating team.",[15],null,[34],{"name":35,"affiliation":5,"role":36},"Patrick C Johnson, MD","PRINCIPAL_INVESTIGATOR",[38],{"name":39,"role":40,"phone":41,"phoneExt":32,"email":42},"Patrick C Johnson","CONTACT","617-724-4000","PCJOHNSON@MGH.HARVARD.EDU",[44],{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Massachusetts General Hospital Cancer Center","RECRUITING","Boston","Massachusetts","02215","United States","US",{"type":53,"coordinates":54},"Point",[55,56],-71.05977,42.35843,{"lat":56,"lon":55},[59],{"name":35,"role":40,"phone":41,"phoneExt":32,"email":42},{"type":36,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":32,"oldOrganization":32},"Patrick C. Johnson, MD","Principal Investigator",[64],{"name":65,"class":6},"Conquer Cancer Foundation","100488935","defining-the-role-of-palliative-care-for-patients-with-hematologic-malignancies-undergoing-adoptive-cellular-therapy-100488935",false,"NCT05646576","Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy","Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy: The PEACE Study","Inclusion Criteria:\n\n* Age 18 years or older.\n* Ability to complete surveys in English or with assistance of an interpreter.\n* Diagnosis of a hematologic malignancy.\n* Receiving autologous adoptive cellular therapy (ACT) at MGH with an FDA approved cellular therapy product.\n\nExclusion Criteria:\n\n* Impaired cognition or uncontrolled mental illness that prohibits study compliance based on the oncology clinician assessment.\n* Already receiving palliative care (PC).","ALL","18 Years",{"count":76,"type":77},90,"ESTIMATED","INTERVENTIONAL",[80],"NA","The goal of this study is to determine whether a palliative care intervention (PEACE) can improve the quality of life and experiences of participants with Lymphoma, Leukemia, or Multiple Myeloma receiving adoptive cellular therapy (ACT). After completion of an open pilot, participants will be randomly assigned into one of two study intervention groups.\n\nThe names of the study intervention groups involved in this study are:\n\n* Palliative care (PEACE) plus usual oncology care\n* Usual care (standard oncology care)\n\nParticipation in this research study is expected to last for up to 2 years.\n\nIt is expected that about 90 people will take part in this research study.",[83,84,85,86,87],"Hematologic Malignancy","Blood Cancer","Lymphoma","Leukemia","Multiple Myeloma",[83,89,90,85,86,87,23],"Adoptive Cellular Therapy","Palliative Care Intervention","2026-04-16",{"date":93,"type":94},"2026-04-21","ACTUAL",{"date":96,"type":94},"2022-12-30",{"date":98,"type":77},"2027-04-01",{"name":5,"class":6},1]